Targeting the Tumor Ecosystem to address cancer drug resistance.
Our compounds disrupt the metabolic and
inflammatory triggers in both cancer and quasi-cancerous
cells in the tumor microenvironment. By impacting multiple cell
types, we are enabling effective, lasting cancer treatments.
Active Founders
